Mediar Therapeutics
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
About Mediar Therapeutics
Mediar Therapeutics is a biotechnology company that develops antibody-based medicines and biologic therapies to address cancer, autoimmune diseases, and other serious health conditions. Its research platform focuses on engineering multi-specific antibodies and modular biologics that can engage multiple biological targets or pathways simultaneously, enabling precise modulation of immune responses. The company’s pipeline includes therapeutic candidates designed to activate or inhibit specific immune functions, with the goal of improving clinical outcomes in oncology and immune-mediated disorders. Mediar Therapeutics also works on scalable manufacturing processes and collaborates with scientific partners to advance its biologics from discovery through clinical development. Its approach integrates protein engineering, immunology, and translational research to create biologic medicines that address complex disease mechanisms. The company continues to refine its technology and expand its therapeutic programs to support future clinical and regulatory progress.
Company Facts
- Headquarters
- Cambridge
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00011_00050
- Funding Stage
- early_stage_venture
- Total Funding
- $181,000,000
- Last Funding Type
- series_b
- Last Funding Date
- 2026-01-07
- Website
- mediartx.com
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Links
Canonical: https://fsome.com/organization/mediar-therapeutics-60504 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.